[{"orgOrder":0,"company":"Flamma SpA","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Remdesivir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Flamma SpA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Flamma SpA \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Flamma SpA \/ Gilead"}]

Find Clinical Drug Pipeline Developments & Deals by Flamma SpA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Flamma has entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury® supply chain. Flamma will continue to use its sites in Italy and China to support Gilead in supplies of the drug f...

                          Brand Name : Veklury

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 05, 2020

                          Lead Product(s) : Remdesivir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank